Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination–deficient stage III/IV ovarian cancer: Findings from cohort C of the OPAL phase 2 trial
Study limitation reported by the research below: “The primary endpoint used an 80% confidence interval rather than the conventional 95%, which may overstate precision of the treatment difference estimate.”